JP2017518273A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518273A5
JP2017518273A5 JP2016565173A JP2016565173A JP2017518273A5 JP 2017518273 A5 JP2017518273 A5 JP 2017518273A5 JP 2016565173 A JP2016565173 A JP 2016565173A JP 2016565173 A JP2016565173 A JP 2016565173A JP 2017518273 A5 JP2017518273 A5 JP 2017518273A5
Authority
JP
Japan
Prior art keywords
drug
inflammatory
sustained release
tooth
root
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016565173A
Other languages
Japanese (ja)
Other versions
JP6644709B2 (en
JP2017518273A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/028305 external-priority patent/WO2015168292A1/en
Publication of JP2017518273A publication Critical patent/JP2017518273A/en
Publication of JP2017518273A5 publication Critical patent/JP2017518273A5/ja
Application granted granted Critical
Publication of JP6644709B2 publication Critical patent/JP6644709B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (16)

歯髄炎を処置するための徐放性薬物送達デバイス。   Sustained release drug delivery device for treating pulpitis. 薬剤が１日より長く放出される、請求項１に記載のデバイス。   The device of claim 1, wherein the drug is released for more than one day. 薬剤が２日〜６カ月の間放出される、請求項１に記載のデバイス。   The device of claim 1, wherein the drug is released for 2 days to 6 months. 徐放性薬物送達デバイスが抗微生物剤および／または抗炎症剤を放出する、請求項１、２および３のいずれか１項に記載のデバイス。   4. A device according to any one of claims 1, 2 and 3, wherein the sustained release drug delivery device releases an antimicrobial and / or anti-inflammatory agent. デバイスが歯根管、歯髄室、象牙質および／または歯肉線の下の歯の外面に配置される、請求項１〜４のいずれか１項に記載のデバイス。   The device according to any one of claims 1 to 4, wherein the device is placed on the outer surface of the tooth under the root canal, pulp chamber, dentin and / or gingival line. デバイス材料が、ヒドロゲルポリマー、無機材料、分解性材料、高分子材料、エラストマー、生物学的に活性な分子および薬剤から構成され、これらの組合せを含む、請求項１〜５のいずれか１項に記載のデバイス。   6. The device of any one of claims 1-5, wherein the device material is composed of a hydrogel polymer, an inorganic material, a degradable material, a polymeric material, an elastomer, a biologically active molecule and a drug, and combinations thereof. The device described. デバイス材料がマイクロ粒子またはナノ粒子の形態である、請求項６に記載のデバイス。   The device of claim 6, wherein the device material is in the form of microparticles or nanoparticles. デバイス材料が事前形成した担体中に入れられる、請求項７に記載のデバイス。   The device of claim 7, wherein the device material is placed in a preformed carrier. 事前形成した担体が、ヒドロゲルポリマー、無機材料、分解性材料、高分子材料、エラストマーおよび生物学的に活性な分子から構成され、これらの組合せを含む、請求項８に記載のデバイス。   9. The device of claim 8, wherein the preformed carrier is composed of hydrogel polymers, inorganic materials, degradable materials, polymeric materials, elastomers and biologically active molecules and includes combinations thereof. 事前形成した担体材料が放射線不透過性である、請求項９に記載のデバイス。   The device of claim 9, wherein the preformed carrier material is radiopaque. 事前形成した担体の開口部が拡散バリアを含有する、請求項１０に記載のデバイス。   12. The device of claim 10, wherein the preformed carrier opening contains a diffusion barrier. 事前形成した担体が、薬剤を含有するマイクロ粒子および／またはナノ粒子を含有するヒドロゲルで充填され、歯内歯髄炎を処置するために薬剤が長時間放出される、請求項１〜１１のいずれか１項に記載のデバイス。   12. The pre-formed carrier is filled with a hydrogel containing microparticles and / or nanoparticles containing a drug and the drug is released for a long time to treat endodontic pulpitis. The device according to item 1. 薬剤が抗炎症剤および／または抗微生物剤である、請求項１２に記載のデバイス。   The device of claim 12, wherein the agent is an anti-inflammatory and / or antimicrobial agent. マイクロ粒子およびナノ粒子が、同一のまたは別々の粒子中に、抗炎症剤および／または抗微生物剤を含有する、請求項１２に記載のデバイス。   13. A device according to claim 12, wherein the microparticles and nanoparticles contain anti-inflammatory and / or antimicrobial agents in the same or separate particles. 哺乳動物において歯髄炎を処置する方法であって、
歯の一部を除去して炎症性の歯根を露出させる工程と、
露出した歯根に薬物を適用する工程と
を含み、
該薬物の適用が徐放性薬物送達デバイスによって行われる前記方法。 A method of treating pulpitis in a mammal, comprising:
Removing a portion of the tooth to expose the inflammatory root;
Applying a drug to the exposed tooth root,
Said method wherein the application of said drug is effected by a sustained release drug delivery device. 哺乳動物において歯髄炎を処置する方法であって、
露出していない炎症性の歯根を有する歯に薬物を適用する工程
を含み、
該薬物の適用が徐放性薬物送達デバイスによって行われる前記方法。 A method of treating pulpitis in a mammal, comprising:
Applying a drug to a tooth having an unexposed inflammatory root;
Said method wherein the application of said drug is effected by a sustained release drug delivery device.
JP2016565173A 2014-04-29 2015-04-29 Endodontic therapy with long-term drug delivery system Active JP6644709B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461985659P 2014-04-29 2014-04-29
US61/985,659 2014-04-29
PCT/US2015/028305 WO2015168292A1 (en) 2014-04-29 2015-04-29 Endodontic treatment with long term drug delivery system

Publications (3)

Publication Number Publication Date
JP2017518273A JP2017518273A (en) 2017-07-06
JP2017518273A5 true JP2017518273A5 (en) 2018-03-29
JP6644709B2 JP6644709B2 (en) 2020-02-12

Family

ID=54359294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565173A Active JP6644709B2 (en) 2014-04-29 2015-04-29 Endodontic therapy with long-term drug delivery system

Country Status (4)

Country Link
EP (1) EP3137011A4 (en)
JP (1) JP6644709B2 (en)
CA (1) CA2947421C (en)
WO (1) WO2015168292A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019030762A2 (en) 2017-08-09 2019-02-14 Stahl Veronica Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects
JP7406809B2 (en) * 2018-03-20 2023-12-28 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Vibrant pulp regeneration
CN114469863B (en) * 2021-11-26 2023-09-26 南方医科大学南方医院 Use of sterol liposomes as drug delivery systems for dental pulp and dentin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
DE4019617A1 (en) * 1990-06-20 1992-01-02 Thera Ges Fuer Patente IMPLANTABLE ACTIVE SUBSTITUTE MATERIAL
JP2959833B2 (en) * 1990-11-06 1999-10-06 ライオン株式会社 Sustained-release oral disease therapeutic agent and method for producing the same
DE19962470A1 (en) * 1999-12-22 2001-07-12 Schulz Hans Herrmann Use of chemotherapy drugs
US20090148486A1 (en) * 2005-04-28 2009-06-11 Helen Lu Compositions and methods for treating pulp inflammations caused by infection or trauma
WO2008103712A2 (en) * 2007-02-20 2008-08-28 Bisco, Inc. Polymerizable dental pulp healing, capping, and lining material and method for use
JP5572291B2 (en) * 2008-04-07 2014-08-13 独立行政法人国立長寿医療研究センター Drug for promoting formation of dental pulp and / or dentin and use thereof
US20120329790A1 (en) * 2009-11-23 2012-12-27 University Of Medicine And Dentistry Of New Jersey Dentinal Drug Delivery Composition
CN102362933B (en) * 2011-10-25 2013-06-19 刘敏 Sustained-release tablet-shaped cachets used for treating toothache caused by excessive internal heat

Similar Documents

Publication Publication Date Title
JP2016509067A5 (en)
JP2017518273A5 (en)
Suzuki et al. Influence of silver nanoparticle solution on the mechanical properties of resin cements and intrarradicular dentin
Ertem et al. Core–shell silver nanoparticles in endodontic disinfection solutions enable long-term antimicrobial effect on oral biofilms
Hiraishi et al. Chlorhexidine release and antibacterial properties of chlorhexidine‐incorporated polymethyl methacrylate‐based resin cement
AR049927A1 (en) ORAL CARE FILM
NZ592325A (en) Extended release oral acetaminophen/tramadol dosage form
TR200200562T2 (en) Pharmaceutical compositions for oral release that can be secreted in the body in a controlled manner and prevent unpleasant taste
PE20121790A1 (en) CONTROLLED RELEASE COMPOSITIONS
DE602004021285D1 (en) WOUND ASSOCIATIONS AND PROCEDURES
MY148495A (en) Oral compositions for treating tooth sensitivity and methods of use and manufacture thereof
Yu et al. Effect of an antibacterial monomer on the antibacterial activity of a pit-and-fissure sealant
Elsaka et al. Antibacterial activity of calcium hydroxide combined with chitosan solutions and the outcomes on the bond strength of RealSeal sealer to radicular dentin
Malic et al. Zeolite-embedded silver extends antimicrobial activity of dental acrylics
PE20091574A1 (en) DRUG ADMINISTRATION SYSTEM WITH STABILIZING EFFECT
Junior et al. Influence of the addition of microsphere load amoxicillin in the physical, chemical and biological properties of an experimental endodontic sealer
DE502006008346D1 (en) MATERIAL FOR THE MOST MEDICAL, LONG-TERM IN-VIVO APPLICATION
Frough Reyhani et al. Comparing the coronal seal of different thicknesses of MTA with gutta-percha after post space preparation
Cecchin et al. Deproteinization technique stabilizes the adhesion of the fiberglass post relined with resin composite to root canal
Chai et al. Evaluation of antimicrobial efficacy of antibiotics and calcium hydroxide against Enterococcus faecalis biofilm in dentine
Barthel et al. Bacterial leakage in roots filled with different medicaments and sealed with Cavit
Maeda et al. An in vitro evaluation of two resin‐based sealers on proliferation and differentiation of human periodontal ligament cells
Nasri et al. Efficacy of MTA modified by nanosilver for the prevention of coronal leakage
Jeon et al. Chlorhexidine-releasing orthodontic elastomerics
Mirza et al. Antibiotics in endodontics